Clinical trial Recruiting at 1 site Interventional

Peer-led support program for young drug abusers

Official title: Effectiveness of a Peer-led Personalized Support Program Using Instant Messaging Applications and a Self-determination Theory-based Intervention to Help Young Drug Abusers Quit Drugs: A Randomized Controlled Trial

Run by Chinese University of Hong Kong · NCT05918601 · Data updated 2026-11-12

This study is testing a new support program led by peers to help young people struggling with drug use quit and improve their overall well-being over a year.

Quick facts

Study typeInterventional
SexAll
Enrollment200 (estimated)
SponsorChinese University of Hong Kong
Academic / other
Locations1 site (Hong Kong)
StatusRecruiting
StartedJune 30, 2023
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedMay 31, 2025
Trial IDNCT05918601 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this program are young individuals aged 35 or below who have a history of drug abuse within the past 12 months and can communicate in Cantonese.

Probably not a fit

Patients who are psychologically or physically unable to communicate will not benefit from this program.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This program aims to evaluate the effectiveness of a peer-led personalized support initiative that utilizes instant messaging applications and self-determination theory to assist young drug abusers in quitting drugs. The study will involve a randomized controlled trial with participants divided into intervention and control groups, focusing on reducing drug use and improving health-related quality of life over a 12-month period. Approximately 200 young drug abusers will be recruited, along with 80 university students trained as peer supporters to facilitate the program. The initiative also includes extensive outreach to raise awareness about drug abuse among young people in Hong Kong.

Why it matters

Potential benefit: If successful, this program could significantly improve the chances of young drug abusers quitting drugs and enhance their overall quality of life.

How similar studies have gone: Other studies have shown success with peer-led interventions for substance abuse, indicating a promising approach for this population.

Who can join: the full rules

Show full inclusion / exclusion criteria
The inclusion criteria of target service group (drug abusers) for this programme:

* be aged 35 or below
* be able to communicate in Cantonese
* have an history of drug abuse within the past 12 months (including all types of drugs such as narcotics analgesics, hallucinogens, depressants, stimulants, tranquillizers and other recreational drugs)

The exclusion Criteria of target service group (drug abusers) for this programme:

* psychologically or physically unable to communicate

The inclusion criteria of peer supporters:

* be aged 18 - 35
* be able to communicate in Cantonese
* have a medical background
* complete the training courses and pass the evaluation of peer supporter qualification

The exclusion Criteria of peer supporters:

* psychologically or physically unable to communicate

Where it's running

  • The Chinese University of Hong Kong
    Hong Kong, Hong Kong
    Recruiting

Study contacts

  • Principal investigator: Ho Cheung William Li — Chinese University of Hong Kong
  • Study coordinator: Ho Cheung William Li
  • Email: williamli@cuhk.edu.hk
  • Phone: 39430889

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.